Logo News Medizin 2000  
        >    Zurück

 | Home | Suche | Nutzung | Impressum| Kontakt |

Themen Websites
Info-Netzwerk MEDIZIN 2000

 

 

 

 

 

Mäuse produzieren menschliche Nieren

 

Rehovot, Israel (December 22, 2002) -- In vielen entwickelten Ländern erweist es sich als schwierig, den Bedarf an Spendernieren zu befriedigen. Jetzt ist es Prof. Yair Reisner am Weizmann Institute of Science, Rehovot, Israel, gelungen, eine Alternative zu entwickeln.

Es gelang dem Team um Prof. Reisner menschliche und Schweine-Stammzellen in Mäuse zu implantieren. Aus diesen Stammzellen wuchsen menschliche Nieren bzw. Schweinenieren, die die Größe von Mäusenieren haben. Diese Nieren werden von den Mäusen nicht abgestoßen. Sie sind funktionsfähig und produzieren Urin. Nach Meinung der Forscher ist es denkbar, dass diese Nieren innerhalb von 2 Jahren bei der Therapie von Nierenversagen eingesetzt werden können.

 

Source:

  Weizmann Institute

Date:

 

12/23/2002

 

Human Kidneys Created In Mice: Transplanted Tissue Could Offer A Solution To Kidney Donor Shortage

Rehovot, Israel (December 22, 2002) -- Instead of searching for a kidney donor, a new study suggests, one might be able to grow a new kidney. A team headed by Prof. Yair Reisner of the Weizmann Institute of Science has induced human stem cell tissue to grow into functional kidneys, and have accomplished the same with porcine stem cell tissue. Published in Nature Medicine, the method could lead to a promising solution to the severe shortage of kidney donors.

The findings suggest that human or porcine fetal tissue might take on the shape and function of a healthy kidney if transplanted into humans as well. Pig tissue, as opposed to pig organs, is not expected to cause hyperacute rejection (common in cross-species transplants), as has been demonstrated by recent transplants of insulin-producing cell clusters taken from porcine fetal tissue that did not induce such rejection. The scientists hope that porcine stem cells might thus provide a ubiquitous source for those in need of a kidney.

According to the U.S. National Kidney Foundation and the United Network for Organ Sharing, more than 50,000 people in the United States alone are on the waiting list for kidney transplants and more than 2,000 died this year waiting for a match. The wait can last years. And after a kidney is transplanted patients run the risk of transplant rejection.

Reisner and Ph.D. student Benny Dekel of the Weizmann Institute's Immunology Department, with Prof. Justen Passwell, the head of the pediatric department at the Sheba Medical Center, transplanted human and porcine "kidney precursor cells" (stem cells that are destined to become kidney cells) into mice. Both human and porcine tissues grew into perfect kidneys, the size of the mice's kidneys. The miniature human and pig kidneys were functional, producing urine. In addition, blood supply within the kidney was provided by host blood vessels as opposed to donor blood vessels, greatly lowering the risk of rejection.

The scientists pinpointed the ideal time during embryonic development in which the stem cells have the best chance to form well-functioning kidneys with minimal risk for immune rejection. Their findings suggest that 7-8 week (human) and 4 week (porcine) tissue offers an optimal window of opportunity for transplantation. If taken at earlier time points the tissues will develop disorganized tissue that would include non-kidney structures such as bone, cartilage, and muscle. If taken at later time points the risk for immune rejection is substantial.

Within this optimal time range the tissue doesn't contain certain cells that the body recognizes as foreign (antigen-presenting cells), the scientists found. These cells, which originate in the blood system, reach a developing kidney only after ten weeks.

After growing the human and porcine kidney tissue in mice, the scientists checked how human lymphocytes (fighter cells in the immune system) might react to it. They injected human lymphocytes into immunodeficient mice (that have no immune system and thus do not interfere with the immune response). The findings were encouraging: as long as the kidney precursors were transplanted within the right time range, the lymphocytes did not attack the new pig or human kidneys – despite the fact that lymphocytes and kidney precursors originated from different donors. Immune rejection was also tested in normal mice and was shown to be reduced compared to that induced by precursors from later time points.

The procedure is now in the pre-clinical study stage. If all goes well, a treatment may ensue within a few years.

 

###

 

Prof. Reisner is the incumbent of the Henry H. Drake Professorial Chair in Immunology. His research is supported by Richard M. Beleson, San Francisco, CA, Renee Companez, Australia, Concern Foundation, Ligue Nationale Francaise Contre Le Cancer, M.D. Moross Institute for Cancer Research, Gabrielle Rich Leukemia Research Foundation, Rowland Schaefer, Pembroke Pines, FL, Union Bank of Switzerland-Optimus Foundation.

The Weizmann Institute of Science, in Rehovot, Israel, is one of the world's foremost centers of scientific research and graduate study. Its 2,500 scientists, students, technicians, and engineers pursue basic research in the quest for knowledge and the enhancement of humanity. New ways of fighting disease and hunger, protecting the environment, and harnessing alternative sources of energy are high priorities at Weizmann.

 


Note: This story has been adapted from a news release issued for journalists and other members of the public. If you wish to quote any part of this story, please credit Weizmann Institute as the original source. You may also wish to include the following link in any citation:

 

mehr Informationen (Originalquelle mit Passwortabfrage für Medizin-Experten)

 

 

 

...................

Seelische Belastungen bei Krebs
Was tun, um mit dieser Krisensituation fertig zu werden?

 

Krebspatienten und ihre Angehörigen leiden unter  kaum erträglichen seelischen Belastungen. Bisher ist wenig darüber bekannt, wie sie mit diesem Problem im Alltag umgehen. Um mehr über die geistig-seelischen Aspekte der Krankheitsbewältigung zu erfahren, wird nun an der Pädagogischen Hochschule Freiburg eine Studie durchgeführt, die sich mit der Frage beschäftigt, wie die betroffenen Menschen ihrer Krebserkrankung umgehen und welche eigenen Möglichkeiten sie hierzu nutzen konnten. Als Grundlage für diese wichtige Studie dient ein online-Fragebogen.  KrebspatientInnen werden von der Autorin Anna-Katharina Burkhardt dazu ermutigt, diesen anonymisierten Fragebogen hier auszufüllen.

 

     
 


  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
   
 

  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
  SIT, spezifische Immuntherapie, Navigation
     

 

 

 

 

 

zum Seitenanfang

 


RSS Newsfeed auf Medizin 2000

Twitter auf Medizin 2000

Werbung auf Medizin 2000

 

Newsletter Immun Plus


Thymus Therapie bei Krebs

Sanorell Workshops Heilpraktiker und Ärzte

Biologischer Bypass Schwarzwald Medical Resort

 


 

 



Wichtige Themen-Websites im Info-Netzwerk Medizin 2000 
(13.12.2009)